Back to search results

A Study of PF-07275315 for Moderate-To-Severe Asthma

This study is looking into the safety and effects of a medicine called PF-07275315 for people with moderate-to-severe asthma. Asthma makes it hard to breathe and can affect your daily life. We are looking for adults aged 18 to 70 who have had moderate-to-severe asthma for at least 12 months that isn't well controlled, even with their usual treatments. You will receive either PF-07275315 or a placebo (a substance with no medicine in it). The main goals are to see how much your breathing (measured by Forced Expiratory Volume in 1 Second or FEV1) improves after 12 weeks and to track any side effects up to 24 weeks. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 252 participants. Participants will be randomly assigned to receive either PF-07275315 or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety and any side effects will be tracked from the beginning of the study through Week 24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06977581

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

Recruiting
PHASE2Ages 18–70InterventionalTreatment
Pfizer
~252 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:PF-07275315Placebo

At a glance

Recruiting sites
110 of 132 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12
Measured over Week 12
+4 more outcomes measured

Conditions

Asthma

Explore related trials

Asthma

Where it's being run

132 sites across 79 states
Seoul-teukbyeolsi [seoul]7
Texas6
California5
Jiangsu4
Taiwan4
Illinois3
North Carolina3
Oklahoma3

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Active helminth or parasitic infection requiring treatment within 2 weeks prior to screening;
Infection requiring hospitalization or systemic (parenteral) antimicrobial therapy within 60 days prior to Day 1;
Any infection judged to be an opportunistic infection or clinically significant by the investigator, within 6 months prior to Day 1.

What this trial measures

  • Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12Week 12

    FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.

  • Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and AEs/SAEs leading to treatment discontinuationBaseline through Week 24

    Incidence of treatment-emergent AEs, treatment-emergent SAEs, and treatment-emergent AEs/SAEs leading to treatment discontinuation

  • Clinically significant, treatment-related laboratory abnormalitiesBaseline through Week 24

    Incidence of clinically significant changes in laboratory tests

  • Clinically significant, treatment-related abnormalities in vital signsBaseline through Week 24

    Incidence of clinically significant changes in vital signs

  • Clinically significant, treatment-related electrocardiogram (ECG) abnormalitiesBaseline through Week 24

    Incidence of clinically significant changes in ECG